Back to JNJView Full Landscape
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
6 competitors in Carcinoma, Non-Small-Cell Lung
PBYIHKI-272
Phase 2LLYIMC-1121B (ramucirumab)
Phase 2CASIrecombinant human Angiostatin protein
Phase 2GTHXG1T38
Phase 2SGENSGN-15
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA1/20/2025
Lazcluze
Lazcluze in combination with amivantamab is indicated for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts